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transplanted MSCs after myocardlal infarction. In the present study. we evaluated effi- 
ciency of lentiviral vector-medIated gene transfer into MSCs and investigated the myo- 
cardial regenerative and angiogenic effect of MSCs transplantation in combination with 
vascular endothelial growth factor (VEGF) gene transfer. Lentiviral vectors containing 
enhanced green fluorescence protein gene were transduced cultured MSCs with more 
than 30% transduction efficiency. Fourty-eight hours after hVEGF121 gene delivery into 
MSCs using lentiviral vectors at titers of 5X1@ infection unit/ml, large amount 
(157.4+45.8 pglml. n=4) of VEGF protein was secreted into the supematant from the 
transduced MSCs. Biochemical or morphological characteristics and differentiation prop- 
erties into cardiomyocytes following 5-azacytidine treatment were not significantly 
changed in the genetically modified MSCs. When VEGF-transfected MSCs (3XlOscells) 
were directly infected into the apex of normal heart, VEGF was secreted until 2 weeks 
after Iantiviral vector-mediated gene transfer to myocardium and concentration gradient 
of VEGF was observed across the left ventricle (apex, 16.1+0.3; mid, 9.0+3.0; base, 
3.3+2 0 pgimg protein of LV). When compared to total concentration (14.Oe2.1 pg/mg 
protein) of secreted VEGF at 1 week after hVEGFl21 gene delivery, myocardial concen- 
tration (26.9+5.4 pglmg protem) of VEGF was significantly greater at 2 weeks. These 
results demonstrate that MSCs transplantation with lentivirus-mediated ex viva VEGF 
gene delivery might be applied in the treatment of ischemic heart disease because thera- 
peutic angiogenesis can be mediated by this treatment strategy in addltlon to myocardial 
regeneration by MSCs transplantation which was already documented. 
1185437 Specific Dysregulation of Troponins and.lnflammatory 
Marker Genes in Endomyocardial Biopsies From Heart 
Transplant Recipients 
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J. Eisen Temple University School of Medicine, Philadelphia, PA, Genelogic. -) 
Gaithersburg, MD 
BACKGROUND: Graft surveillance by protocol biopsies can reflect the 
immunological status of the graft as well as the efficacy of 
anti-relection therapy. However, standard morphological features of 
endomyocardial biopsies do not necessarily correlate wth graft function 
or prognosticate future rejection episodes. The goal of this work is fo 
identify objectwe, specific, and quantitative surrogate markers of 
graft rejection and function. 
METHODS: A novel and proprietary micro sample ampllflcation (MSA) 
technique has been developed to r&ably amplify mRNA in a non-anomalous 
and non-disproportionate manner from nanogram quantities of RNA. MSA 
was used to generate a transcriptional profile of gene expression from 
endomyocardial biopsies from different International Society of Heart 
and Lung Transplant (ISHLT) rejection grades. 
RESULTS. This study demonstrates that expression of Tropomn I, 
Troponin T2, and Troponin C are proporhonal to the ISHLT rejection 
grade, with more mRNA of each transcript being detected in grade 3A 
versus IA biopsies. This is significant I” that the Troponin family of 
proteins regulate muscle contraction by cyclin sequestration. 
Similarly, expression of several IFNg-inducible genes are also expressed 
in a rejection grade manner. In particular, the IFNg-inducible gene 
IF130 was specifically detected only in grade 3A samples. IF130 has been 
characterized as a lysosomal thlol reductase that is important in 
antigen processing. 
CONCLUSIONS: MSA is novel technique to identify gene expression in 
lImIted tissue samples such as biopsies. Specifically, the Troponins and 
IFl30, in confunction with other genes may represent surrogate molecular 
markers of the status of allografl rejection and function in cardiac 
transplant recipients. 
1185-88 Enhanced Cardiomyocyte Transplantation With 
Vascular Endothelial Growth Factor and IGF 
Transduction in a Mouse Model of Acute Myocardial 
infarction 
Masatomo Nakao, Jennifer Cho, Richard Wu, Erin Lewis, Feiran Lou. Haoyi Zheng, Rui 
Lui. Shunichi Homma. Marlo Deng, Hal A. Skopicki, Columbia University New York, NY, 
North Shore Uwersity Hospital, Manhasset. NY 
Despite many claims of widespread successes, cardiomyocyte transplantation is limited 
by issues including cell viability and the availability of donor cells. We tested the hypothe- 
sis thar both viability and angiogemc signals, transduced into a subpopulation of trans- 
planted cardiomyocytes, would enhance survival of the transplanted grail. h vitro, cells 
transfected with IGF-1 plasmid or m&a contalnlng IGF-1 protein demonstrated 
enhanced suwival(42 * 11% and 51 * 8%; both ~~0.05 compared to untransfected cells, 
26 t 6%) at 46 hours. No additional suwival effect was seen with transfected VEGF165 
or in the presence of VEGF protein. When transplanted into the periinfarct region of mice 
two weeks after LAD Ilgation, neonatal cardiomyocytes alone, or cells transferred in a 
solution containing VEGF and IGF protein. formed sparse stable grafts in viva associated 
with persistent decline in myocardial contractility (net decrease in fractional shortening 
0.7% f 0.6% and 4.9% r 1.6%, respectively) at 3 weeks. However, markedly enhanced 
cellular survival, coupled with augmentation I” myocardial contractility (net increase I” 
fracfional shortening +8 3% * 1.7%). were present in grafts that were anchored by the 
presence of neonatal cardlomyocytes expressmg IGF-1 and VEGFI 65 plasmlds and that 
were also transplanted in the presence of growth factor proteins. These data demon- 
strate clinically relevant. limited survival of untreated rransplanted cardlomyocytes into 
the perlinfarct region of mouse myocardium and enhanced graft survival and functional 
augmentation only after transplantation both in the presence of peptide growth factors 
and cells genetically modified to enhance survival (IGF) and promote vascularization 
(VEGF). 
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855-1 Elevated Levels of the CXCRB Chemokine Ligand ITAC 
Is Associated With the Development of Severe 
Transplant Coronary Artery Disease in Humans 
John Kaq Jon Kobashigawa, Micheal C. Flshbein, Robb C. Mac Lellan, Marie Burdick, 
John Belperio, Robert M. Stricter, UCLA G&en School of Medicine, Los Angeles, CA 
Background: For patients undergolng orthotopic heart transplanta6w the major cause 
of late graft loss is transplant coronary artery disease (TCAD). CCR5 and CXCRB 
chemokine ligands have been implicated as causative factors in the development of 
acute rejection. however they have not been assessed in TCAD. Methods and Results: 
Serum levels of chemokines were measured by ELISA. Of the CCR5 and CXCRB 
chemokines studied. only ITAC was elevated I” patients with severe TCAD (n=l5), com- 
pared lo long-term survivors (11.15) without transplant coronary disease, and healthy. 
non-transplanted volunteers (n=9). Serum levels of ITAC were 1.476+/-0.274 @ml, 
0.926+/-0.466 ng/ml, and 0.741 +/- 0.321 @ml, respectively. P=O.O49 for the interaction 
of the three, p=O.74 for Control vs. No TCAD, p=O.O34 for NO TCAD vs. TCAD. and 
~~0.043 for Control vs TCAD. lmmunohistochemical localization confirmed the presence 
of CXCR3+ mononuclear cells within lessons and the presence of the ligand, ITAC, on 
the endothekal surface of TCAD lesions. 
CXCR3 Ligand Levels 
Conlrol No TCAD TCAD P Value 
ITAC @g/ml) 0.741+/-0.321 0.926+/-0.466 1.476+/-0.274 0.034’ 
0.043’” 
Mlg @g/ml) 0.071 0.015 
IP-10 @g/ml) 0.04 0 
‘TCAD vs No TCAD. *‘Control “s TCAD 
0.023 NS 
0 NS 
Conclusions: Elevated peripheral blood levels of the CXCRB chemokine ITAC is associ- 
ated with the development of severe TCAD. and may serve as a marker for patients at 
increased risk for the development of this disease. lmmunohistochemical localization the 
CXCR3 chemokine ligand ITAC on the endothelium of lesions with underlying infiltration 
of inflammatory mononuclear cells expressing CXCRB supports a causative role for the 
development of TCAD. 
2:15 p.m. 
855-2 Noninvasive Prediction of Coronary Stenoses in Heart 
Allografts Without Regional Wall Motion Disturbances 
and Normal Left Ventricular Ejection Fraction 
Michael Dandel Friedrich Knollmann, Ernst Wellnhofer. Manfred Hummel, Roland 
Hetzer, Deutsches Herzzentrum, Berlin, Germany 
Background: Although most transplant centers perform annually routine coronary angiog- 
raphies for screening, this surveillance often fail to detect coronary stenoses prior to a 
clinical event. After obtaining promising results for early transplant coronary artery dis- 
ease diagnosis separately with pulsed-wave tissue Doppler imaging [PW-TDI] and elec- 
tron beam computed tomography [EBCT], we assessed the hypothesis that both 
methods in a combined use could further improve allografl vasculopathy surveillance, 
especially in patients with apparently rwrmal left ventricular (LV) function. 
Methods: Throughout 16 months, 169 consecutive patients with post-transplant times 
over 1 year, normal LV ejection fraction and lack of relevant reglonal wall motion dlstur- 
bances underwent EBCT (coronary calcification detection) and PW-TDI (LV wall motion 
analysis) before coronary angiography. Coronary calcifications were quantified by the 
Agatston scoring system. With PW-TDI we measured the systolic and diastolic wall 
motion peak velocities (Sm and Em) and the systolic and diastolic times (TSm from onset 
of first heart sound to Sm and TEm from onset of second heart sound to Em) EBCT and 
PW-TDI data were tested for relationshios with anaioaraphic findmas. _ _ 
Results: The systolic peak velocity (Sm) and total calcification score (TCS) showed the 
hlohest predictive values. We found sianlficant differences Io=O.OOOl) between Datlents _ 
with and without proximal stenoses of great epicardial coronary vessels for both TCS and 
Sm. Relevant coronary stenoses (> 50% occlusion) were absent in 99.2% of patients 
with Sm > 9 cmls and TCS values c 75. Using both Sm and TCS together, these cut-off 
values allowed the separation of a group of 126 patients with low probability of coronary 
stenoses (125 free from stenoses) and a group of 63 patients which included 96.7% of all 
patients with coronary stenoses and only 16.1% of all patients wIthout stenoses. 
